# Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone

> **NCT00907452** · NA · COMPLETED · sponsor: **Intergroupe Francophone du Myelome** · enrollment: 143 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** melphalan-prednisone-thalidomide
- **DRUG:** lenalidomide-dexamethasone

## Key facts

- **NCT ID:** NCT00907452
- **Lead sponsor:** Intergroupe Francophone du Myelome
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-29
- **Primary completion:** 2010-12-14
- **Final completion:** 2016-07-14
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907452, "Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00907452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*